Dr David Kerr on a first-of-its-kind analysis revealing that much work is needed to alleviate the burden on colleagues worldwide.

Dr Mark Kris pays tribute to a true giant in the field of oncology and his dear friend, Jimmie Holland.

Dr Kathy Miller responds to a recent New York Times article documenting rare immunotherapy responses, which may lead to false hope among cancer patients and their families.

Dr David Kerr on how this time-tested drug enhances more complex and expensive immunotherapies.

Authors of a recent ASCO statement on diversity discuss their experiences and suggestions for improving inclusivity in the oncology workforce.

Dr Jeffrey S. Weber reviews data from an open-label phase 1/2 trial assessing the efficacy and safety of combination pembrolizumab and reduced-dose ipilimumab in patients with advanced melanoma.

ICD use in patients with CKD, PFO and peri-operative stroke, LV assist devices, guideline-directed medical therapy after revascularization, and upcoming trials in 2018 are discussed in this week's podcast.

Dr David Kerr on data showing that tumors with extensive aneuploidy may not benefit as much from immune checkpoint blockade.

Dr Kathy Miller speaks with APHINITY's principal investigator about whether survival in HER2+ disease can be pushed even further.

Know the appropriate indications for transfusion when transfusion is not indicated in patients with sickle cell disease.